Levi & Korsinsky, LLP announces that it has commenced an investigation of TG Therapeutics, Inc. (NASDAQ: TGTX) concerning possible violations of federal securities laws by the Company and/or certain of its officers and directors.
TG Therapeutics, Inc. issued a press release on October 13, 2016 announcing that the Company had filed an amended protocol with the FDA for its leukemia drug combination, GENUINE Phase 3 Trial. In the amendments, the Company eliminated part II of the GENUINE study and reduced the number of randomized patients from 200 to approximately 120. The Company further announced it no longer benefits from its previously negotiated Special Protocol Assessment with the FDA.
To receive more information, please fill out the form.